Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates.

The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders (KOLs) to generate a targeted 1,000–2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT® code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.